FDA Approves Tarlatamab-Dlle to Treat Adults With Extensive Stage Small Cell Lung Cancer
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Tarlatamab-dlle: A Beginning for Bispecific Therapies in Small Cell Lung Cancer
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Introducing Tarlatamab-dlle: A New Era in Oncology Treatment
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Positive New Data Highlighting Tarlatamab-dlle Safety, Anticancer Activity Presented at WCLC 2024
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Vivek Subbiah: US FDA granted accelerated approval to tarlatamab-dlle
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.